Kingdom Investment Holdings

12/24/2025

In healthcare, speed often gets the attention.
But long-term impact is built through patience, clarity, and restraint.

The most meaningful progress comes from decisions made with tomorrow in mind, not just today’s momentum.

Join the conversation on what thoughtful leadership looks like in healthcare. kit-llc.com

12/23/2025

In healthcare, innovation without structure creates variability.

Patent licensing exists to provide a framework for consistency, accountability, and responsible use, particularly as new technologies move into real-world clinical settings.

At Kingdom Investment Holdings, we view licensing as a stewardship responsibility, not a barrier. Learn more: kingdomlicensing.com.

12/23/2025

🔥 BIG NEWS in weight-loss care: The FDA just approved oral semaglutide (Wegovy) as the first once-daily GLP-1 pill for weight loss and reducing cardiovascular risk — a major milestone for people who want a non-injectable option in the obesity treatment space. This pill showed real efficacy in clinical trials and will launch in the U.S in January 2026.

👉 This matters because semaglutide works by activating the GLP-1 pathway to reduce appetite and support sustained weight loss — the same mechanism trusted in injectable Wegovy.

But let’s cut past the hype: one pill doesn’t solve access, affordability, or convenience for every patient. Insurance barriers, dosing constraints, and individual tolerability still leave gaps in real-world adoption.

That’s where compounded Semaglutide in SubMagna® HMW comes in:

✅ No needles.

✅ Customizable dosing.

✅ Potential sublingual delivery that bypasses injections and GI absorption hurdles.

✅ A cost-effective option when traditional prescriptions are inaccessible or unaffordable.

Many patients want real convenience and real affordability — not just another branded pill with high list prices. Compounded semaglutide in SubMagna® HMW offers an innovative, needle-free alternative that’s uniquely tailored and doesn’t anchor patients to supply chains or insurance formularies.

💡 Bottom line: Oral GLP-1 pills are a welcome addition to the obesity toolkit — but personalized compounding with SubMagna® HMW gives patients a real-world alternative when injections or pricey brand therapies fall short.

Compounded medications are not reviewed by FDA for safety or efficacy.

The FDA approves Wegovy, the first oral GLP-1 pill, offering a new weight loss solution for those struggling with obesity and overweight.

12/22/2025

12/17/2025

12/15/2025

Pharmacy innovation doesn’t fail because of lack of ideas.
It fails because of fragmentation.

Today’s pharmacy landscape is siloed.
Licensing lives in one place.
Drug delivery innovation in another.
Compounding, access, pricing, research, and patient impact are all disconnected.

When innovation is fragmented, progress slows. Costs rise. Patients wait.

Kingdom Investment Holdings exists to solve that problem.

KIH integrates every critical layer of pharmacy innovation under one ecosystem:
• Intellectual property and licensing
• Advanced drug delivery platforms
• Compounding and manufacturing support
• Pharmacy access and purchasing power
• Research-backed education
• And real-world patient impact

Instead of isolated solutions, we build connected systems that move innovation from concept to care faster, safer, and more sustainably.

This is what happens when pharmacy innovation is designed to work together, not apart.

Integration isn’t the future of pharmacy.
It’s the requirement.

12/13/2025

🔥 Big News in GLP-1 Delivery Research! 🔥

Compounded Semaglutide in SubMagna® HMW just appeared in a peer-reviewed pharmacokinetics article on ScienceDirect - demonstrating that sublingual delivery of semaglutide is actively being studied and reported in the scientific literature!

The study investigates single-dose pharmacokinetics comparing sublingual, oral, and injectable semaglutide - which is exactly the kind of scientific conversation we want around next-gen compounded semaglutide dosing innovations.

This isn’t just hype - it’s data visibility and scientific footprint for compounded formulations using SubMagna® HMW in a field dominated by oral and injectable formulations. That’s a meaningful step toward broader awareness and validation of alternative peptide delivery approaches.

🚀 What this means:

• Scientific recognition of sublingual routes for semaglutide

• SubMagna® HMW is part of the pharmacokinetics discourse

• A boost in credibility for clinicians and compounding pharmacies exploring advanced GLP-1 delivery

Let’s keep pushing forward - real science, real publications, real progress. 💡

Compounded medications are not reviewed by FDA for safety or efficacy.

PCCA PCCA UK +

12/12/2025

When Kingdom companies grow, charitable impact grows with them.

If the remainder of this month closes as expected, Kingdom Luxe Travel will book up to $6,000,000 in 2025 travel, generating approximately $600,000 in commissions — with $300,000 directed to approved 501(c)(3) organizations.

The same model applies across Kingdom initiatives. As SubMagna®, BASSAGEL™, and other platforms expand, so does the charitable impact tied to them.

This isn’t symbolic giving.
It’s impact structurally embedded in the business model.

See Kingdom Luxe Travel’s post for the travel details.

SubMagna HMW Kingdom Luxe Travel

12/11/2025

Every Kingdom Investment Holdings company serves a purpose, and together they create a powerful, integrated ecosystem where innovation, access, and philanthropy work in unison.

At the foundation is Kingdom Licensing, the IP engine that protects and advances breakthrough technologies like SubMagna® HMW and BASSAGEL.
These innovations fuel our Product Layer, where SubMagna® HMW enables advanced sublingual delivery for complex molecules and BASSAGEL provides a versatile, water-washable base for topical, wound, skin, and hair applications.

Our Cost and Access Layer, KIH-GPO, ensures independent pharmacies can access essential medications at better pricing, strengthening the compounding pipeline that relies on technologies like SubMagna® HMW.

And on the lifestyle side, Kingdom Luxe Travel transforms premium travel bookings into meaningful impact by donating half of commission revenue directly to vetted nonprofits.

KIH is the connective tissue.

Innovation, commerce, and global philanthropy all working together to build a smarter, more generous ecosystem with every product, partnership, and booking. At the intersection of entrepreneurship and philanthropy is where you find KIH.